The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report

• Main Authors: Nikolai A. Ognerubov, Tatyana S. Antipova
• Format: Article
• Language: Russian
• Published: IP Habib O.N. 2021-08-01
• Series: Современная онкология
• Subjects: small cell lung cancer; pd-1/pd-l1 checkpoint inhibitors; atezolizumab; combined positron emission and x-ray computed tomography
• Online Access: https://modernonco.orscience.ru/1815-1434/article/viewFile/72330/pdf
• ISSN: 1815-1434; 1815-1442

Background. Lung cancer (LC) occupies a leading position among malignant tumors in the world, it accounts for 11.4% of the total malignant neoplasms. In 2020, there were 2 206 771 new cases of LC and 1 796 144 deaths worldwide. Among the histological variants, small cell LC (SCLC) has the most unfavorable outcomes. This variant is considered highly sensitive to chemotherapy. Despite some successes in the treatment of this disease, the results of treatment remain problematical. In recent years, the use of immune checkpoint inhibitors has provided significant control of the course of the disease. Aim. To show the efficacy of atezolizumab in combination with chemotherapy in patients with metastatic SCLC. Materials and methods. A 76-year-old patient with left lung cancer, IVA T4N3M1b, the right supraclavicular lymph node metastases, exudative pleuritis of the left lung was under observation. The histological investigation showed SCLC. Brain metastases were not detected. ECOG 0. Results. The patient was treated using atezolizumab 1200 mg in combination with carboplatin 5 AUC and etoposide 100 mg/m2 on days 1, 2, 3 for four cycles, followed by a maintenance therapy regimen with atezolizumab 1200 mg every 21 days. The patient received 21 injections during 14 months. The assessment of treatment effect was evaluated using combined 18F-fluorodeoxyglucose positron emission and X-ray computed tomography. As a result of the treatment, after 7 months, a complete clinical and morpho-metabolic regression of the tumor was reached, which persisted throughout the period of the treatment. Among the adverse events were detected grade 2 anemia and first-stage sensory neuropathy. No immune-related adverse events were observed. Conclusion. The addition of atezolizumab to etoposide + carboplatin as the first-line therapy for extensive-stage SCLC provides the long-term overall and disease-free survival with achieving the satisfactory quality of life in patients and acceptable drug tolerance.